of the data takes place in agreement and cooperation with the HVB. The data contains no names of individual patients or health care provider. All unique identifiers, such as the social security number, have been removed along with postal codes and the date of birth for the patients. Only district information and year of birth is available. All team members working with the data have signed a confidentiality agreement and declaration of commitment ensuring that research will be undertaken in accordance with the applicable data protection regulations. A security clearance for this database signed by MUV's legal department that states that individuals are not identifiable is enclosed in this submission. to be diagnosed with osteoporosis when compared to men, whereas females without statin treatment (control group) only have a 1.99-fold (p<0.01) increased risk for osteoporosis compared to males. In younger age groups (below 70 years), this effect was particularly strong. Furthermore, OR-intra increases as a function of age in both groups. 
Supplementary

Supplementary table S5: Individual statin dosage-dependent ORs of osteoporosis (95% CI) obtained from the logistic regression model for females (pink) and males (blue):
Interpretation:
In the sex-specific analysis only low dose simvastatin treatment is related to an To test whether or not the observed dosage-dependent trend is independent of the identified comorbidity groups, we performed a multiple logistic regression analysis with the difference that the patients of the respective confounding disease group were excluded to investigate their influence on ORs development. The obtained results of each regression were visualized as one graphic, to compare the individual risk trajectories. The figure above presents the dosage-dependent osteoporosis risk trajectories for the individual disease groups of simvastatin. The baseline (black) denote all individuals treated with simvastatin and their dosage-dependent osteoporosis risk development. The other 11 trajectories display how the risk develops when patients of a particular disease group are excluded. The figure shows that all trajectories follow the same trend that a higher dose is associated with higher incidence of osteoporosis diagnosis. Although we observe a higher variance of ORs in the highest dosage category (>60-80 mg), the differences can be neglected as they are likely to result from the small case numbers of this dosage category. This is indicated by the large confidence intervals. The interpretation of the results is further confirmed by the results of other statins as shown in supplementary figure S3 ,S4,S5,S6,S7.
